Biosignatures: Comparative effectiveness research in biomarker clinical studies
Due to increased healthcare expenditure and the need for evidence-supported clinical decision-making, clinical evaluation using comparative effectiveness research (CER) was initially proposed in the US. CER consists of generating and synthesizing evidence in relative benefits, harms, and costs of di...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2012-06-01
|
Series: | Journal of the Formosan Medical Association |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S0929664612001441 |
id |
doaj-72738c8955384c1bbec044aa094a44ba |
---|---|
record_format |
Article |
spelling |
doaj-72738c8955384c1bbec044aa094a44ba2020-11-24T23:06:23ZengElsevierJournal of the Formosan Medical Association0929-66462012-06-01111630030410.1016/j.jfma.2011.12.011Biosignatures: Comparative effectiveness research in biomarker clinical studiesJur-Shan Cheng0David Bin-Shiun Wu1Yu Wen Wen2Pi-Hua Liu3Jr-Rung Lin4Chee-Jen Chang5Clinical Informatics and Medical Statistics Research Center, Chang Gung University, Taoyuan, TaiwanDivision of Biostatistics, Institute of Public Health, National Yang Ming University, Taipei, TaiwanClinical Informatics and Medical Statistics Research Center, Chang Gung University, Taoyuan, TaiwanClinical Informatics and Medical Statistics Research Center, Chang Gung University, Taoyuan, TaiwanClinical Informatics and Medical Statistics Research Center, Chang Gung University, Taoyuan, TaiwanClinical Informatics and Medical Statistics Research Center, Chang Gung University, Taoyuan, TaiwanDue to increased healthcare expenditure and the need for evidence-supported clinical decision-making, clinical evaluation using comparative effectiveness research (CER) was initially proposed in the US. CER consists of generating and synthesizing evidence in relative benefits, harms, and costs of different alternatives through direct head-to-head comparisons. CER studies can help identify the most effective interventions for patients under specific circumstances, and therefore improve the efficiency of the healthcare system. A Biosignatures project newly launched in Taiwan was inspired by CER, aiming at using discovered biomarkers panel as tools in early detection of disease and prediction of treatment effectiveness.http://www.sciencedirect.com/science/article/pii/S0929664612001441biomarkerbiosignaturescomparative effectiveness research (CER)evidence based medicine (EBM)randomized clinical trials (RCT) |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Jur-Shan Cheng David Bin-Shiun Wu Yu Wen Wen Pi-Hua Liu Jr-Rung Lin Chee-Jen Chang |
spellingShingle |
Jur-Shan Cheng David Bin-Shiun Wu Yu Wen Wen Pi-Hua Liu Jr-Rung Lin Chee-Jen Chang Biosignatures: Comparative effectiveness research in biomarker clinical studies Journal of the Formosan Medical Association biomarker biosignatures comparative effectiveness research (CER) evidence based medicine (EBM) randomized clinical trials (RCT) |
author_facet |
Jur-Shan Cheng David Bin-Shiun Wu Yu Wen Wen Pi-Hua Liu Jr-Rung Lin Chee-Jen Chang |
author_sort |
Jur-Shan Cheng |
title |
Biosignatures: Comparative effectiveness research in biomarker clinical studies |
title_short |
Biosignatures: Comparative effectiveness research in biomarker clinical studies |
title_full |
Biosignatures: Comparative effectiveness research in biomarker clinical studies |
title_fullStr |
Biosignatures: Comparative effectiveness research in biomarker clinical studies |
title_full_unstemmed |
Biosignatures: Comparative effectiveness research in biomarker clinical studies |
title_sort |
biosignatures: comparative effectiveness research in biomarker clinical studies |
publisher |
Elsevier |
series |
Journal of the Formosan Medical Association |
issn |
0929-6646 |
publishDate |
2012-06-01 |
description |
Due to increased healthcare expenditure and the need for evidence-supported clinical decision-making, clinical evaluation using comparative effectiveness research (CER) was initially proposed in the US. CER consists of generating and synthesizing evidence in relative benefits, harms, and costs of different alternatives through direct head-to-head comparisons. CER studies can help identify the most effective interventions for patients under specific circumstances, and therefore improve the efficiency of the healthcare system. A Biosignatures project newly launched in Taiwan was inspired by CER, aiming at using discovered biomarkers panel as tools in early detection of disease and prediction of treatment effectiveness. |
topic |
biomarker biosignatures comparative effectiveness research (CER) evidence based medicine (EBM) randomized clinical trials (RCT) |
url |
http://www.sciencedirect.com/science/article/pii/S0929664612001441 |
work_keys_str_mv |
AT jurshancheng biosignaturescomparativeeffectivenessresearchinbiomarkerclinicalstudies AT davidbinshiunwu biosignaturescomparativeeffectivenessresearchinbiomarkerclinicalstudies AT yuwenwen biosignaturescomparativeeffectivenessresearchinbiomarkerclinicalstudies AT pihualiu biosignaturescomparativeeffectivenessresearchinbiomarkerclinicalstudies AT jrrunglin biosignaturescomparativeeffectivenessresearchinbiomarkerclinicalstudies AT cheejenchang biosignaturescomparativeeffectivenessresearchinbiomarkerclinicalstudies |
_version_ |
1725623316020985856 |